Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04984525 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers
A Phase 1 study of Healthy, sponsored by Synlogic.
- Completed
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
- 1
- Study location
NCT04984525 is a Phase 1 study of Healthy that has completed, run by Synlogic. The registered enrollment target is 106 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04984525, a Phase 1 study of Healthy, has completed, sponsored by Synlogic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
- 1
- Study location
Study Summary
This Phase 1, first-in-human, multiple dose-escalation, randomized, double-blinded, placebo-controlled study is evaluating SYNB1934 in healthy volunteers (HV). Eligible subjects receive investigational product (IP) and undergo safety monitoring, evaluations, and subsequent follow-up after IP administration.
Conditions Studied
Interventions
- DRUG SYNB1934
- DRUG SYNB1618
Study Locations (1)
North Carolina
- High Point Clinical Trials Center - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2021-07-02 |
| Est. Completion | 2021-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04984525
The ClinicalTrials.gov registry entry for NCT04984525 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (84% lower). The listed sponsor is Synlogic, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which SYNB1934 is the first listed.
NCT04984525 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04984525 about?
NCT04984525 is a clinical study titled "Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers". This Phase 1, first-in-human, multiple dose-escalation, randomized, double-blinded, placebo-controlled study is evaluating SYNB1934 in healthy volunteers (HV). Eligible subjects receive investigational product (IP) and undergo safety monitoring, evaluations, and subsequent follow-up after IP adminis...
What is the current status of trial NCT04984525?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2021-07-02. Estimated completion is 2021-12-10.
What conditions does trial NCT04984525 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT04984525?
The interventions under investigation include: SYNB1934 (DRUG), SYNB1618 (DRUG).
Who is sponsoring clinical trial NCT04984525?
This trial is sponsored by Synlogic, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04984525 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.